Clinical Trial Update: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 study evaluated the diagnostic accuracy of Gallium-68-DOTATATE PET/CT compared with Indium-111-pentetreotide SPECT/CT for gastroenteropan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• Gallium-68 DOTATATE PET/CT (Gallium-68 DOTATATE)
• Indium-111 pentetreotide scintigraphy (SPECT/CT) (Indium-111 pentetreotide)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 1, Phase 2 | Status: TERMINATED